 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- Development and characterization of a novel CDK4/6 inhibitor for the treatment of CDK4/6 dependent cancers (Section 9; Poster Board #20) - Mar 14, 2023 - Abstract #AACR2023AACR_8585;
P1
We evaluated the clinically approved CDK4/6 inhibitors, palbociclib, ribociclib and abemaciclib
- ||| UCT-03-008 / 1200 Pharma
Enrollment open, Metastases: First in Human Study of UCT-03-008 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Feb 10, 2022
P1, N=68, Recruiting, Sponsor: 1200 Pharma, LLC
We evaluated the clinically approved CDK4/6 inhibitors, palbociclib, ribociclib and abemaciclib Not yet recruiting --> Recruiting
- ||| UCT-03-008 / 1200 Pharma
New P1 trial, Metastases: First in Human Study of UCT-03-008 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Nov 2, 2021
P1, N=68, Not yet recruiting, Sponsor: 1200 Pharma, LLC